Br[C:2]1[C:10]2[C:5](=[N:6][CH:7]=[CH:8][C:9]=2[N+:11]([O-:13])=[O:12])[N:4]([CH2:14][O:15][CH2:16][CH2:17][Si:18]([CH3:21])([CH3:20])[CH3:19])[CH:3]=1.[CH3:22]B1OB(C)OB(C)O1.C(=O)([O-])[O-].[K+].[K+]>CN(C=O)C>[CH3:22][C:2]1[C:10]2[C:5](=[N:6][CH:7]=[CH:8][C:9]=2[N+:11]([O-:13])=[O:12])[N:4]([CH2:14][O:15][CH2:16][CH2:17][Si:18]([CH3:21])([CH3:20])[CH3:19])[CH:3]=1A solution of 80 mg (210 μmol) of 3-bromo-4-nitro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine, 27 mg (210 μmol) of trimethylboroxine, 25 mg (20 μmol) of tetrakis(tri-phenylphosphine)palladium and 103 mg (640 μmol) of potassium carbonate in 2.00 ml of degassed DMF is stirred in a sealed pressure vessel at 110° C. for 6 h and then at RT overnight. The suspension is then filtered through an Extrelut silica gel cartridge, the cartridge is washed with a mixture of dichloromethane/methanol 1:1 and the filtrate is concentrated under reduced pressure. The residue is purified by preparative RP-HPLC.
Loading…
